WSJ
30 Jun 2026, 09:35 UTC · 2h ago
Genmab Shares Climb After Lymphoma Therapy Hits Goal in Trial
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
WSJ
30 Jun 2026, 09:35 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
1 claim · each scored for market impact
A lymphoma drug combination developed by a Danish biotech company and AbbVie met its primary goal in a late-stage clinical trial. — Success in late-stage trials significantly increases the probability of regulatory approval and future commercial revenue.
+0.80Which stocks this story touches
Continue reading
6 related stories
Search tags
[mutual] AbbVie and Genmab are partners in a clinical trial for a lymphoma drug combination.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Newsfile Corp
12h ago
